Plasma Protein Binding and PK/PD of Total and Unbound Temocillin Non-ICU Patients
NCT ID: NCT03557840
Last Updated: 2022-05-31
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
NA
Total Enrollment
60 participants
Study Classification
INTERVENTIONAL
Study Start Date
2019-04-01
Study Completion Date
2023-04-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Multidrug resistance towards Gram-negative pathogens makes essential the re-examination of older compounds. Temocillin is a penicillin originally marketed in the 1980s but then largely abandoned. It, however, shows a marked ß-lactamase stability (including most classical and extended-spectrum TEM, SHV, CTX-M enzymes and AmpC ß-lactamase). Temocillin is approved for the treatment of bacterial infections of the chest, the lungs, the kidney, the bladder, as well as bacterial infections of the bloodstream and wound infections.
Temocillin efficacy depends primarily from the time interval during which the unbound plasma concentration remains above the minimal inhibitory concentration (MIC) of the antibiotic against the target organism(s). Unfortunately, no comprehensive pharmacokinetic data are available in non-critically-ill patients.
The primary objective of the study is characterize the pharmacokinetics of total and unbound temocillin in non-ICU patients, and, on this basis, to propose optimized dosage regimens in this population. The secondary objectives are (i) to look for possible correlations between the plasma protein profile and the unbound temocillin concentrations; (ii) to investigate the impact of the level and nature of circulating plasma proteins on the unbound temocillin concentration.
The study will be non-randomized, uncontrolled, prospective, open label, interventional, and monocentric. It will include a population pharmacokinetic-pharmacodynamic analysis of the data obtained. The study will enroll patients ≥ 18 years in need of a treatment with temocillin for (i) complicated urinary tract infection and pyelonephritis (associated or not with bacteremia), or (ii) lower respiratory tract infection, or (iii) abdominal infection, and requiring ≥ 4 days of hospitalization. Blood samples will be obtained at day 0 (control) and after 2 and 4 days of drug treatment (full pharmacokinetic evaluation over 8 to 12 h post-administration). Total and unbound temocillin concentrations in plasma will be quantified by a validated analytical method.
A population pharmacokinetic/pharmacodynamics model of plasma total and unbound concentrations of temocillin will be obtained by Bayesian algorithms using Pmetrics software, driven by the predicted plasma total and unbound concentration. The model will be used to assess the probability of target attainment of temocillin.
Temocillin efficacy depends primarily from the time interval during which the unbound plasma concentration remains above the minimal inhibitory concentration (MIC) of the antibiotic against the target organism(s). Unfortunately, no comprehensive pharmacokinetic data are available in non-critically-ill patients.
The primary objective of the study is characterize the pharmacokinetics of total and unbound temocillin in non-ICU patients, and, on this basis, to propose optimized dosage regimens in this population. The secondary objectives are (i) to look for possible correlations between the plasma protein profile and the unbound temocillin concentrations; (ii) to investigate the impact of the level and nature of circulating plasma proteins on the unbound temocillin concentration.
The study will be non-randomized, uncontrolled, prospective, open label, interventional, and monocentric. It will include a population pharmacokinetic-pharmacodynamic analysis of the data obtained. The study will enroll patients ≥ 18 years in need of a treatment with temocillin for (i) complicated urinary tract infection and pyelonephritis (associated or not with bacteremia), or (ii) lower respiratory tract infection, or (iii) abdominal infection, and requiring ≥ 4 days of hospitalization. Blood samples will be obtained at day 0 (control) and after 2 and 4 days of drug treatment (full pharmacokinetic evaluation over 8 to 12 h post-administration). Total and unbound temocillin concentrations in plasma will be quantified by a validated analytical method.
A population pharmacokinetic/pharmacodynamics model of plasma total and unbound concentrations of temocillin will be obtained by Bayesian algorithms using Pmetrics software, driven by the predicted plasma total and unbound concentration. The model will be used to assess the probability of target attainment of temocillin.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Temocillin Pharmacokinetics in Paediatrics
NCT02260102
Infection
Liver Dysfunction
Urinary Tract Infection
UNKNOWN
PHASE4
Pharmacokinetics of Piperacillin/Tazobactam in Patients Treated by Continuous Renal Replacement Therapy
NCT00703144
Diffusive and Convective Clearance
Body Clearance
Piperacillin Tazocilline Concentrations (Cmin)
COMPLETED
PHASE4
Pharmacokinetics of Teicoplanin in Intensive Care and Haematology Patients
NCT04096092
Bacterial Infections
COMPLETED
Retrospective Observational Study of Cotrimoxazole Dosing in Intensive Care Unit
NCT05221216
Acute Kidney Injury
COMPLETED
Pharmacokinetics of Piperacillin and Tazobactam in Critically Ill Patients
NCT03738683
Bacterial Infections
COMPLETED
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1.1. Introduction.
Multidrug resistance towards gram-negative pathogens has been increasing dramatically over the last decades. Due to insufficient discovery of drugs acting on novel targets, re-examination of older compounds, such as temocillin, for which resistance is still low, has proven to be of great therapeutic interest.
As all the β-lactams, temocillin efficacy depends primarily on the time interval during which the plasma concentration remains above the minimal inhibitory concentration (MIC) of the antibiotic against the target organism(s) (Craig, 1998). It is generally accepted that the unbound concentration of the antibiotic must remain above the MIC for at least 40 to 70% of the interval between two successive administrations, and should even reach 100% for severe infections in patients hospitalized in Intensive Care Units (MacGowan, 2011).
Temocillin (Negaban®), a ß-lactamase-resistant penicillin antibiotic, was first marketed in the 1980s but then abandoned due to a lack of activity against anaerobes, gram-positive bacteria and Pseudomonas aeruginosa (Livermore et al., 2006; Zykov et al., 2016). However, temocillin stability to ß-lactamases (including classical and extended-spectrum TEM, SHV, CTX-M enzymes and AmpC ß-lactamase) has found great appreciation amongst a large number of professionals in the field (Balakrishnan et al., 2011; Livermore and Tulkens, 2009). It is approved for intravenous and intramuscular administration at a dose ranging between 1-2 g twice - thrice - a day for the treatment of bacterial infections of the chest, the lungs, the kidney, the bladder, as well as bacterial infections of the bloodstream, abdominal infection, and wound infections (RCP Temocillin, 2014).
Studies performed in critical ill patients show important variations in the level of plasma proteins and rapid and unpredictable fluctuations in renal function (Beumier et al., 2015; Goncalves-Pereira and Povoa, 2011; Roberts and Lipman, 2009), both of which are known to modulate the pharmacokinetics of β-lactams (Goncalves-Pereira and Povoa, 2011; Hayashi et al., 2013; Sime et al., 2012; Udy et al., 2012; Wong et al., 2013). As a consequence, the unbound concentration of β-lactams with high protein binding (Schleibinger et al., 2015; Ulldemolins et al., 2011; Van Dalen et al., 1987; Wong et al., 2013), and renal elimination (Carlier et al., 2013; Simon et al., 2006; Vandecasteele et al., 2015) such as temocillin will be markedly modified in these patients.
The pharmacokinetics of total and unbound temocillin together with its plasma protein binding have been recently investigated in clinical studies performed in healthy volunteers and in critical-ill patients. The first results show that plasma protein binding of temaocillin was concentration-dependent in both populations but much more important in healthy volunteers compared to critically-ill patients), resulting in a lower unbound concentration of temocillin in healthy volunteers as compared to critically ill patients.
These studies were conducted in two extreme populations, but temocillin is more widely used in patients who do not require hospitalization in an intensive care unit. It would therefore be of high interest to study the pharmacokinetics of temocillin in non-critically-ill patients, including its protein binding, in order to estimate whether the current dosing regimen is optimal to reach PK/PD targets predictive of efficacy.
1.2. Study objectives.
1.2.1. Primary objectives.
* To characterize the pharmacokinetics of total and unbound temocillin using population pharmacokinetic and pharmacodynamics modeling and to calculate and assess the values of key pharmacokinetic parameters (total clearance, volume of distribution, constants of elimination, plasma total and unbound maximal and minimal concentrations) in patients hospitalized in standard care wards.
* To propose optimized dosage regimens in this population, as compared to what could be proposed for patients hospitalized in intensive care units.
Secondary objectives:
1.2.2. Secondary objectives.
* To look for possible correlations between the plasma protein profile and the unbound temocillin concentrations;
* To investigate the impact of the level and nature of circulating plasma proteins on the unbound temocillin concentration.
1.3. Study design.
Non-randomized control trial, prospective, open label, interventional, monocentric, population pharmacokinetic and pharmacodynamics.
1.4. Study population.
1.4.1. Sample size calculation.
As a descriptive pharmacokinetic study without formal predefined hypothesis, no calculation of the size of the population has been made. Based on literature data and our own experience, a maximum of 60 patients should be sufficient to draw meaningful conclusions.
1.4.2. Study groups and number of patients
The population studied is divided according to their pathology into 3 groups
* Group 1: 15 to 30 patients with complicated urinary tract infection and pyelonephritis associated or not with bacteraemia.
* Group 2: 15 to 30 patients with lower respiratory tract infection.
* Group 3: 15 to 30 patients with abdominal infection.
In a first step, each group will undergo a thorough pharmacokinetic study. In a second step we will study the pharmacokinetics of all pooled data and the results obtained will make it possible to compare the parameters.
1.4.3. Inclusion criteria (see elsewhere)
1.4.4. Exclusion criteria (see elsewhere)
1.4.5. Reason for withdrawal of study: at the patient's own request; in case of lack of cooperation, change of medication, occurrence of adverse event(s), or other objections to participate in the study in the opinion of the investigator
1.5. Study drug.
Temocillin (NEGABAN®) 2 g will be administered as intravenous infusion over 30 minutes 2 or 3 times a day. The patient's physician will decide on the duration of temocillin use.
1.5.1. Indications.
Temocillin is indicated for treatment of the infections mentioned in the protocol.
1.5.2. Contraindications.
The use of Temocillin (NEGABAN®) is contraindicated in patients with a history of allergic reactions to any of the penicillins or any other type of beta-lactam drug.
1.5.3. Undesirable effects: diarrhoea, pain at site of injection, occasionally rash (urticarial or erythematous), fever, arthralgia or myalgia, sometimes developing more than 48 hours after treatment initiation, angioedema and anaphylaxis. In patients suffering from renal failure, neurological disorders with convulsions have been reported following i.v. injection of high dose of penicillins.
1.6. Study protocol.
Upon signature of the informed consent form and provided that the inclusion/exclusion criteria are fulfilled, subjects will be enrolled in the study. Only the procedure of management of the patients of the hospital where the study will be conducted will be taken into account in this study. Only patients verifying inclusion criteria will be accepted.
1.6.1. Study day.
1.6.1.1. Study day 1.
Control (Blood Sampling before dosing)
1.6.1.2. Study day 2.
Determination of total and unbound temocillin concentrations in plasma, will be performed after intravenous administration. Plasma samples will be collected at defined time points before the dose administration and during up to 8 hours (if the dose is 2g/8h) or up to 12 hours (if the dose is 2g/12h).
1.6.1.3. Study day 4.
Determination of total and unbound temocillin concentrations in plasma, will be performed after intravenous administration of 2g of temocillin. Plasma samples will be collected at defined time points before the dose administration and during up to 8 hours (if the dose is 2 g/8 h) or up to 12 hours (if the dose is 2 g/12 h).
1.7. Study duration.
The expected total duration of the trial (recruitment) is 24 months (or more if patient enrollment is slow).
2\. Methods.
2.1. Sampling period's instructions.
Blood sampling will be performed over 8 or 12 hours. Venous blood will be drawn from a suitable antecubital vein at defined time points before and after study drug administration.
Time points will be as follows: If dose administration is 2g/8h
* Day 1: Control (before dosing),
* Day 2 and 4: T0 + 30 min, 1, 2, 4, 6, and 8 hours after study drug administration.
* T0: time after end of infusion.
Time points will be as follows: If dose administration is 2g/12h
* Day 1: Control (before dosing)
* Day 2 and 4: T0 + 30 min, 1, 2, 4, 6, 8, and 12 hours after study drug administration.
* T0: time after end of infusion.
2.2. Blood collection tube and volume.
* Blood collection tube: EDTA tube (plasma) without ball or gel
* Blood volume per tube: 5mL
* Total blood volume by kinetics: 45mL The blood samples will be placed on ice immediately after collection and subsequently centrifuged (2000g, 10 minutes, 4°C). Resulting plasma will be aliquoted and frozen at -80°C until analysis.
Collection of bacterial strains from the patient All bacterial strains identified in the biological samples of each patient will be conserved
2.3 and 2.4: Flow Charts (available on request).
2.5. Total and unbound temocillin quantification.
Total and unbound temocillin concentrations in plasma samples will be quantified using a validated liquid chromatography - tandem mass spectrometry (LC-MS/MS) method (Ngougni Pokem et al., 2015).
For determination of the total temocillin,- concentration, assay will be performed after plasma protein precipitation with methanol. Unbound concentrations will be determined after ultracentrifugation of samples using Amicon filter Ultra-15 device; NMWL 30K; Merck Millipore Ltd) TMO.
2.6. Demographic and Laboratory data.
The following laboratory investigations will be collected
* Age,
* Body weight and body mass index (BMI),
* Calculated Glomerular filtration rate (GFR)
* Total protein and albumin level
2.7. Labeling.
2.7.1. Patient identification.
Each enrolled patient will be identified by the first letter of the first name and the first letter of the surname. Patient numbers 01 - 60 will be used in a consecutive order.
2.7.2. Sample identification.
Each sample will be clearly and unequivocally identified with a label resistant to the storage temperature and containing the following information:
* Type of infection
* patient number
* Scheduled time of sampling (hh:min)
2.8. Statistical and pharmacokinetic data analysis.
Statistical analysis will be performed using commercially available softwares (JMP Pro and Graph Pad Prism). Primary pharmacokinetic outcome variables (area under the curve \[AUC\], volume of distribution \[Vd\], total drug clearance \[Cl\]), and maximal and minimal concentration \[Cmax, Cmin\] will be displayed as means ± standard deviation (SD) given normal distribution of the data, or as medians and interquartile range if data are not normally distributed. Normal distribution of the data will be assessed by means of boxplots, Q-Q plots. Graphs showing the concentration-time profiles of total and unbound temocillin will be presented.
2.9. Population pharmacokinetic and pharmacodynamics analysis.
2.9.1. Model building.
The Population pharmacokinetic and pharmacodynamics (Pop-PK/PD) model of plasma total and unbound concentrations of temocillin will be analysed and fitted by Bayesian algorithms using non-commercially available software programs (Pmetrics software version1.4.1 ; LAPKB, Los Angeles, CA, USA.), driven by the predicted plasma total and unbound concentration.
One-, two and three-compartmental pharmacokinetic models will be fitted to the plasma temocillin pharmacokinetic data set. The model which best describes the data will be selected to drive the unbound temocillin concentration pharmacokinetic model in plasma.
Multidrug resistance towards gram-negative pathogens has been increasing dramatically over the last decades. Due to insufficient discovery of drugs acting on novel targets, re-examination of older compounds, such as temocillin, for which resistance is still low, has proven to be of great therapeutic interest.
As all the β-lactams, temocillin efficacy depends primarily on the time interval during which the plasma concentration remains above the minimal inhibitory concentration (MIC) of the antibiotic against the target organism(s) (Craig, 1998). It is generally accepted that the unbound concentration of the antibiotic must remain above the MIC for at least 40 to 70% of the interval between two successive administrations, and should even reach 100% for severe infections in patients hospitalized in Intensive Care Units (MacGowan, 2011).
Temocillin (Negaban®), a ß-lactamase-resistant penicillin antibiotic, was first marketed in the 1980s but then abandoned due to a lack of activity against anaerobes, gram-positive bacteria and Pseudomonas aeruginosa (Livermore et al., 2006; Zykov et al., 2016). However, temocillin stability to ß-lactamases (including classical and extended-spectrum TEM, SHV, CTX-M enzymes and AmpC ß-lactamase) has found great appreciation amongst a large number of professionals in the field (Balakrishnan et al., 2011; Livermore and Tulkens, 2009). It is approved for intravenous and intramuscular administration at a dose ranging between 1-2 g twice - thrice - a day for the treatment of bacterial infections of the chest, the lungs, the kidney, the bladder, as well as bacterial infections of the bloodstream, abdominal infection, and wound infections (RCP Temocillin, 2014).
Studies performed in critical ill patients show important variations in the level of plasma proteins and rapid and unpredictable fluctuations in renal function (Beumier et al., 2015; Goncalves-Pereira and Povoa, 2011; Roberts and Lipman, 2009), both of which are known to modulate the pharmacokinetics of β-lactams (Goncalves-Pereira and Povoa, 2011; Hayashi et al., 2013; Sime et al., 2012; Udy et al., 2012; Wong et al., 2013). As a consequence, the unbound concentration of β-lactams with high protein binding (Schleibinger et al., 2015; Ulldemolins et al., 2011; Van Dalen et al., 1987; Wong et al., 2013), and renal elimination (Carlier et al., 2013; Simon et al., 2006; Vandecasteele et al., 2015) such as temocillin will be markedly modified in these patients.
The pharmacokinetics of total and unbound temocillin together with its plasma protein binding have been recently investigated in clinical studies performed in healthy volunteers and in critical-ill patients. The first results show that plasma protein binding of temaocillin was concentration-dependent in both populations but much more important in healthy volunteers compared to critically-ill patients), resulting in a lower unbound concentration of temocillin in healthy volunteers as compared to critically ill patients.
These studies were conducted in two extreme populations, but temocillin is more widely used in patients who do not require hospitalization in an intensive care unit. It would therefore be of high interest to study the pharmacokinetics of temocillin in non-critically-ill patients, including its protein binding, in order to estimate whether the current dosing regimen is optimal to reach PK/PD targets predictive of efficacy.
1.2. Study objectives.
1.2.1. Primary objectives.
* To characterize the pharmacokinetics of total and unbound temocillin using population pharmacokinetic and pharmacodynamics modeling and to calculate and assess the values of key pharmacokinetic parameters (total clearance, volume of distribution, constants of elimination, plasma total and unbound maximal and minimal concentrations) in patients hospitalized in standard care wards.
* To propose optimized dosage regimens in this population, as compared to what could be proposed for patients hospitalized in intensive care units.
Secondary objectives:
1.2.2. Secondary objectives.
* To look for possible correlations between the plasma protein profile and the unbound temocillin concentrations;
* To investigate the impact of the level and nature of circulating plasma proteins on the unbound temocillin concentration.
1.3. Study design.
Non-randomized control trial, prospective, open label, interventional, monocentric, population pharmacokinetic and pharmacodynamics.
1.4. Study population.
1.4.1. Sample size calculation.
As a descriptive pharmacokinetic study without formal predefined hypothesis, no calculation of the size of the population has been made. Based on literature data and our own experience, a maximum of 60 patients should be sufficient to draw meaningful conclusions.
1.4.2. Study groups and number of patients
The population studied is divided according to their pathology into 3 groups
* Group 1: 15 to 30 patients with complicated urinary tract infection and pyelonephritis associated or not with bacteraemia.
* Group 2: 15 to 30 patients with lower respiratory tract infection.
* Group 3: 15 to 30 patients with abdominal infection.
In a first step, each group will undergo a thorough pharmacokinetic study. In a second step we will study the pharmacokinetics of all pooled data and the results obtained will make it possible to compare the parameters.
1.4.3. Inclusion criteria (see elsewhere)
1.4.4. Exclusion criteria (see elsewhere)
1.4.5. Reason for withdrawal of study: at the patient's own request; in case of lack of cooperation, change of medication, occurrence of adverse event(s), or other objections to participate in the study in the opinion of the investigator
1.5. Study drug.
Temocillin (NEGABAN®) 2 g will be administered as intravenous infusion over 30 minutes 2 or 3 times a day. The patient's physician will decide on the duration of temocillin use.
1.5.1. Indications.
Temocillin is indicated for treatment of the infections mentioned in the protocol.
1.5.2. Contraindications.
The use of Temocillin (NEGABAN®) is contraindicated in patients with a history of allergic reactions to any of the penicillins or any other type of beta-lactam drug.
1.5.3. Undesirable effects: diarrhoea, pain at site of injection, occasionally rash (urticarial or erythematous), fever, arthralgia or myalgia, sometimes developing more than 48 hours after treatment initiation, angioedema and anaphylaxis. In patients suffering from renal failure, neurological disorders with convulsions have been reported following i.v. injection of high dose of penicillins.
1.6. Study protocol.
Upon signature of the informed consent form and provided that the inclusion/exclusion criteria are fulfilled, subjects will be enrolled in the study. Only the procedure of management of the patients of the hospital where the study will be conducted will be taken into account in this study. Only patients verifying inclusion criteria will be accepted.
1.6.1. Study day.
1.6.1.1. Study day 1.
Control (Blood Sampling before dosing)
1.6.1.2. Study day 2.
Determination of total and unbound temocillin concentrations in plasma, will be performed after intravenous administration. Plasma samples will be collected at defined time points before the dose administration and during up to 8 hours (if the dose is 2g/8h) or up to 12 hours (if the dose is 2g/12h).
1.6.1.3. Study day 4.
Determination of total and unbound temocillin concentrations in plasma, will be performed after intravenous administration of 2g of temocillin. Plasma samples will be collected at defined time points before the dose administration and during up to 8 hours (if the dose is 2 g/8 h) or up to 12 hours (if the dose is 2 g/12 h).
1.7. Study duration.
The expected total duration of the trial (recruitment) is 24 months (or more if patient enrollment is slow).
2\. Methods.
2.1. Sampling period's instructions.
Blood sampling will be performed over 8 or 12 hours. Venous blood will be drawn from a suitable antecubital vein at defined time points before and after study drug administration.
Time points will be as follows: If dose administration is 2g/8h
* Day 1: Control (before dosing),
* Day 2 and 4: T0 + 30 min, 1, 2, 4, 6, and 8 hours after study drug administration.
* T0: time after end of infusion.
Time points will be as follows: If dose administration is 2g/12h
* Day 1: Control (before dosing)
* Day 2 and 4: T0 + 30 min, 1, 2, 4, 6, 8, and 12 hours after study drug administration.
* T0: time after end of infusion.
2.2. Blood collection tube and volume.
* Blood collection tube: EDTA tube (plasma) without ball or gel
* Blood volume per tube: 5mL
* Total blood volume by kinetics: 45mL The blood samples will be placed on ice immediately after collection and subsequently centrifuged (2000g, 10 minutes, 4°C). Resulting plasma will be aliquoted and frozen at -80°C until analysis.
Collection of bacterial strains from the patient All bacterial strains identified in the biological samples of each patient will be conserved
2.3 and 2.4: Flow Charts (available on request).
2.5. Total and unbound temocillin quantification.
Total and unbound temocillin concentrations in plasma samples will be quantified using a validated liquid chromatography - tandem mass spectrometry (LC-MS/MS) method (Ngougni Pokem et al., 2015).
For determination of the total temocillin,- concentration, assay will be performed after plasma protein precipitation with methanol. Unbound concentrations will be determined after ultracentrifugation of samples using Amicon filter Ultra-15 device; NMWL 30K; Merck Millipore Ltd) TMO.
2.6. Demographic and Laboratory data.
The following laboratory investigations will be collected
* Age,
* Body weight and body mass index (BMI),
* Calculated Glomerular filtration rate (GFR)
* Total protein and albumin level
2.7. Labeling.
2.7.1. Patient identification.
Each enrolled patient will be identified by the first letter of the first name and the first letter of the surname. Patient numbers 01 - 60 will be used in a consecutive order.
2.7.2. Sample identification.
Each sample will be clearly and unequivocally identified with a label resistant to the storage temperature and containing the following information:
* Type of infection
* patient number
* Scheduled time of sampling (hh:min)
2.8. Statistical and pharmacokinetic data analysis.
Statistical analysis will be performed using commercially available softwares (JMP Pro and Graph Pad Prism). Primary pharmacokinetic outcome variables (area under the curve \[AUC\], volume of distribution \[Vd\], total drug clearance \[Cl\]), and maximal and minimal concentration \[Cmax, Cmin\] will be displayed as means ± standard deviation (SD) given normal distribution of the data, or as medians and interquartile range if data are not normally distributed. Normal distribution of the data will be assessed by means of boxplots, Q-Q plots. Graphs showing the concentration-time profiles of total and unbound temocillin will be presented.
2.9. Population pharmacokinetic and pharmacodynamics analysis.
2.9.1. Model building.
The Population pharmacokinetic and pharmacodynamics (Pop-PK/PD) model of plasma total and unbound concentrations of temocillin will be analysed and fitted by Bayesian algorithms using non-commercially available software programs (Pmetrics software version1.4.1 ; LAPKB, Los Angeles, CA, USA.), driven by the predicted plasma total and unbound concentration.
One-, two and three-compartmental pharmacokinetic models will be fitted to the plasma temocillin pharmacokinetic data set. The model which best describes the data will be selected to drive the unbound temocillin concentration pharmacokinetic model in plasma.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Pharmacokinetics
Antibacterial Agents
Infections, Bacterial
Infection
Drug Monitoring
Temocillin
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
All patients will be simultaneously studied (disregarding the nature of their infection or the dose/schedule of temocillin)
Primary Study Purpose
OTHER
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Temocillin treatment
Patients treated with temocillin and sampled as per the protocol
Group Type
EXPERIMENTAL
temocillin
Intervention Type
DRUG
Drug dosing and blood sampling as per the protocol
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
temocillin
Drug dosing and blood sampling as per the protocol
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
NEGABAN
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ≥ 18 years old
* prescribed temocillin for a complicated urinary tract infection and pyelonephritis associated or not with bacteraemia; or a l ower respiratory tract infection; or an abdominal infection
* requiring ≥ 4 days hospitalization
* having signed and informed consent (or signed by the legal representative)
* prescribed temocillin for a complicated urinary tract infection and pyelonephritis associated or not with bacteraemia; or a l ower respiratory tract infection; or an abdominal infection
* requiring ≥ 4 days hospitalization
* having signed and informed consent (or signed by the legal representative)
Exclusion Criteria
* Patients \< 18 years old
* Patients allergic to β-lactams
* Patients Ig-E mediated allergy to penicillin
* Patients with acute or chronic renal failure (GFR \< 30ml/min)
* Patients having participated in another study \< 30 days before inclusion in the present study
* Patients allergic to β-lactams
* Patients Ig-E mediated allergy to penicillin
* Patients with acute or chronic renal failure (GFR \< 30ml/min)
* Patients having participated in another study \< 30 days before inclusion in the present study
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Paul M. Tulkens
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Paul M. Tulkens
Professor
Responsibility Role
SPONSOR_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Françoise Van Bambeke, PharmD, PhD
Role: STUDY_DIRECTOR
Université cathollique de Louvain, Louvain Drug Research Institute
Paul M. Tulkens, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Université catholique de Louvain, Louvain Drug Research Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
AZ Delta ziekenhuis
Roeselare, West-Vlaanderen, Belgium
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Belgium
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Balakrishnan I, Awad-El-Kariem FM, Aali A, Kumari P, Mulla R, Tan B, Brudney D, Ladenheim D, Ghazy A, Khan I, Virgincar N, Iyer S, Carryn S, Van de Velde S. Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and/or derepressed AmpC beta-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother. 2011 Nov;66(11):2628-31. doi: 10.1093/jac/dkr317. Epub 2011 Aug 2.
Reference Type
RESULT
Beumier M, Casu GS, Hites M, Wolff F, Cotton F, Vincent JL, Jacobs F, Taccone FS. Elevated beta-lactam concentrations associated with neurological deterioration in ICU septic patients. Minerva Anestesiol. 2015 May;81(5):497-506. Epub 2014 Sep 15.
Reference Type
RESULT
Carlier M, Carrette S, Roberts JA, Stove V, Verstraete A, Hoste E, Depuydt P, Decruyenaere J, Lipman J, Wallis SC, De Waele JJ. Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used? Crit Care. 2013 May 3;17(3):R84. doi: 10.1186/cc12705.
Reference Type
RESULT
Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998 Jan;26(1):1-10; quiz 11-2. doi: 10.1086/516284.
Reference Type
RESULT
Goncalves-Pereira J, Povoa P. Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of beta-lactams. Crit Care. 2011;15(5):R206. doi: 10.1186/cc10441. Epub 2011 Sep 13.
Reference Type
RESULT
Hayashi Y, Lipman J, Udy AA, Ng M, McWhinney B, Ungerer J, Lust K, Roberts JA. beta-Lactam therapeutic drug monitoring in the critically ill: optimising drug exposure in patients with fluctuating renal function and hypoalbuminaemia. Int J Antimicrob Agents. 2013 Feb;41(2):162-6. doi: 10.1016/j.ijantimicag.2012.10.002. Epub 2012 Nov 13.
Reference Type
RESULT
Livermore DM, Hope R, Fagan EJ, Warner M, Woodford N, Potz N. Activity of temocillin against prevalent ESBL- and AmpC-producing Enterobacteriaceae from south-east England. J Antimicrob Chemother. 2006 May;57(5):1012-4. doi: 10.1093/jac/dkl043. Epub 2006 Mar 10. No abstract available.
Reference Type
RESULT
Livermore DM, Tulkens PM. Temocillin revived. J Antimicrob Chemother. 2009 Feb;63(2):243-5. doi: 10.1093/jac/dkn511. Epub 2008 Dec 18.
Reference Type
RESULT
Ramsdale EH, Hargreave FE. Differences in airway responsiveness in asthma and chronic airflow obstruction. Med Clin North Am. 1990 May;74(3):741-51. doi: 10.1016/s0025-7125(16)30549-1.
Reference Type
RESULT
Ngougni Pokem P, Miranda Bastos AC, Tulkens PM, Wallemacq P, Van Bambeke F, Capron A. Validation of a HPLC-MS/MS assay for the determination of total and unbound concentration of temocillin in human serum. Clin Biochem. 2015 May;48(7-8):542-5. doi: 10.1016/j.clinbiochem.2015.02.006. Epub 2015 Feb 21.
Reference Type
RESULT
RCP Temocillin. Temocillin Summary of Product Characteristics. Centre Belge d'Information Pharmacothérapeutique (C.B.I.P.asbl) . 2014. 4-1-2016 http://bijsluiters.fagg-afmps.be/registrationSearchServlet?key=BE467724&leafletType=rcp
Reference Type
RESULT
Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med. 2009 Mar;37(3):840-51; quiz 859. doi: 10.1097/CCM.0b013e3181961bff.
Reference Type
RESULT
Schleibinger M, Steinbach CL, Topper C, Kratzer A, Liebchen U, Kees F, Salzberger B, Kees MG. Protein binding characteristics and pharmacokinetics of ceftriaxone in intensive care unit patients. Br J Clin Pharmacol. 2015 Sep;80(3):525-33. doi: 10.1111/bcp.12636. Epub 2015 Jun 11.
Reference Type
RESULT
Sime FB, Roberts MS, Peake SL, Lipman J, Roberts JA. Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review. Ann Intensive Care. 2012 Jul 28;2(1):35. doi: 10.1186/2110-5820-2-35.
Reference Type
RESULT
Simon N, Dussol B, Sampol E, Purgus R, Brunet P, Lacarelle B, Berland Y, Bruguerolle B, Urien S. Population pharmacokinetics of ceftriaxone and pharmacodynamic considerations in haemodialysed patients. Clin Pharmacokinet. 2006;45(5):493-501. doi: 10.2165/00003088-200645050-00004.
Reference Type
RESULT
Udy AA, Varghese JM, Altukroni M, Briscoe S, McWhinney BC, Ungerer JP, Lipman J, Roberts JA. Subtherapeutic initial beta-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest. 2012 Jul;142(1):30-39. doi: 10.1378/chest.11-1671.
Reference Type
RESULT
Ulldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet. 2011 Feb;50(2):99-110. doi: 10.2165/11539220-000000000-00000.
Reference Type
RESULT
Van Dalen R, Vree TB, Baars IM. Influence of protein binding and severity of illness on renal elimination of four cephalosporin drugs in intensive-care patients. Pharm Weekbl Sci. 1987 Apr 24;9(2):98-103. doi: 10.1007/BF01960743.
Reference Type
RESULT
Vandecasteele SJ, Miranda Bastos AC, Capron A, Spinewine A, Tulkens PM, Van Bambeke F. Thrice-weekly temocillin administered after each dialysis session is appropriate for the treatment of serious Gram-negative infections in haemodialysis patients. Int J Antimicrob Agents. 2015 Dec;46(6):660-5. doi: 10.1016/j.ijantimicag.2015.09.005. Epub 2015 Oct 9.
Reference Type
RESULT
Wong G, Briscoe S, Adnan S, McWhinney B, Ungerer J, Lipman J, Roberts JA. Protein binding of beta-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations? Antimicrob Agents Chemother. 2013 Dec;57(12):6165-70. doi: 10.1128/AAC.00951-13. Epub 2013 Sep 30.
Reference Type
RESULT
Zykov IN, Sundsfjord A, Smabrekke L, Samuelsen O. The antimicrobial activity of mecillinam, nitrofurantoin, temocillin and fosfomycin and comparative analysis of resistance patterns in a nationwide collection of ESBL-producing Escherichia coli in Norway 2010-2011. Infect Dis (Lond). 2016 Feb;48(2):99-107. doi: 10.3109/23744235.2015.1087648. Epub 2015 Sep 28.
Reference Type
RESULT
Wijnant GJ, Ngougni Pokem P, Coessens M, Cottone E, Ermtraud J, Goeman L, Vervaeke S, Wicha SG, Van Bambeke F. Pharmacokinetics and pharmacological target attainment of standard temocillin dosing in non-critically ill patients with complicated urinary tract infections. J Antimicrob Chemother. 2024 Sep 3;79(9):2204-2212. doi: 10.1093/jac/dkae215.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
temocillin prot-bind non-ICU
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
The OPTIMAL TDM Study: Determining Optimal Beta-lactam Plasma Concentrations Through Therapeutic Drug Monitoring
NCT03790631
COMPLETED
Antibiotic Dosing in Geriatric Patients At the Emergency Department
NCT04436991
RECRUITING
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis
NCT06672978
RECRUITING
PHASE2
Pharmacokinetic Parameters of Co-trimoxazole
NCT01832987
COMPLETED
PHASE2
Disturbance of the Intestinal Microbiota by Temocillin vs Cefotaxime in Treatment of Febrile Urinary Tract Infections
NCT02959957
COMPLETED
PHASE4
Pharmacokinetic Study,Ceftobiprole,Healthy Volunteers,Healthy Patients With End Stage Renal Disease
NCT01030731
COMPLETED
PHASE1
Model for PK/PD of Antimicrobials in Blood Stream Infection: Feasibility
NCT04083443
UNKNOWN
Efficacy of Temocillin in Urinary Tract Infection Due to ESBL Producing and AmpC Hyperproducing Enterobacteriaceae
NCT02681263
UNKNOWN
PHASE4
Study of Adverse Effects Occuring in Patients Receiving an Antibiotic Treatment With Temocillin
NCT03599999
COMPLETED
PCR Technic Evaluation in the Microbial Diagnostic of Septicemia in Hemodialysis Patients With Catheter.
NCT04026035
COMPLETED
Pharmacokinetics of Flucloxacillin Given by Continuous or Intermittent Infusion to ICU Patients
NCT02993575
COMPLETED
Therapeutic Drug Monitoring and Continuous Infusion of Beta-lactam Antibiotics in Patients With Bacteraemia
NCT03108690
WITHDRAWN
PHASE4
Prolonged Infusion Cefepime and Nosocomial Infections
NCT02568800
UNKNOWN
PHASE3
A Pharmacokinetics Study of MK-7655A in Pediatric Participants With Gram-negative Infections (MK-7655A-020)
NCT03230916
COMPLETED
PHASE1
A Study to Investigate PK, Safety, Tolerability of Cefepime-enmetazobactam in Pediatric Participants With cUTI
NCT05826990
RECRUITING
PHASE2
Colistin Pharmacokinetics in Critically Ill Patients During Extended Dialysis
NCT02556190
COMPLETED
Pharmacokinetics of Retapamulin in Pediatric Subjects With Uncomplicated Skin Infections.
NCT00555061
COMPLETED
PHASE4
Evaluation of Pharmacokinetic and Pharmacodynamic Properties of Intravenous Colistimethate Sodium
NCT02288429
COMPLETED
Personalized Optimization of Antibiotic Therapy in Pulmonary Sepsis Critically Ill Patients Through Application of Rapid Microbiological Diagnostic Technologies and Pharmacokinetic/Pharmacodynamic Modelling
NCT06956053
NOT_YET_RECRUITING
NA
Assessment of the Optimal Dosing of Piperacillin-tazobactam in Intensive Care Unit Patients: Extended Versus Continuous Infusion
NCT01198925
COMPLETED
PHASE4
Pharmacokinetic and Pharmacodynamic Evaluation of Linezolid Administered Intravenously in MRSA-positive, Morbidly Obese Patients With Pneumonia
NCT01805284
COMPLETED
PHASE4
A Safety and Tolerability Study of Doripenem Compared With Meropenem in Children Hospitalized With Complicated Intra-abdominal Infections
NCT01110382
TERMINATED
PHASE3
Optimizing Clinical Use of Polymyxin B
NCT02682355
COMPLETED
Short-term Antibiotic Therapy for Pyelonephritis in Childhood
NCT00724256
TERMINATED
PHASE3
Evaluation of the Dosing Regimen of Vancomycin in Pediatric Patients
NCT03560440
COMPLETED